Page last updated: 2024-10-21

4-aminopyridine and Brain Ischemia

4-aminopyridine has been researched along with Brain Ischemia in 5 studies

Brain Ischemia: Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.

Research Excerpts

ExcerptRelevanceReference
"5 mg D-ER, 10 mg D-ER, or placebo, dosed twice-daily for 12 weeks."2.94A double-blind, randomized, controlled study of two dose strengths of dalfampridine extended release on walking deficits in ischemic stroke. ( Bockbrader, M; El-Feky, WH; Finklestein, SP; Goldstein, M; Kasner, SE; Ning, M; Page, SJ; Roberts, H; Wilson, CA, 2020)

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's3 (60.00)29.6817
2010's0 (0.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Page, SJ1
Kasner, SE1
Bockbrader, M1
Goldstein, M1
Finklestein, SP1
Ning, M1
El-Feky, WH1
Wilson, CA1
Roberts, H1
Takagi, H1
Kodama, K1
Saito, M1
Suzuki, H1
Bancila, V1
Nikonenko, I1
Dunant, Y1
Bloc, A1
Sperlágh, B1
Zsilla, G1
Vizi, ES1
Schaeffer, P1
Lazdunski, M1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
This is a Multi-center, Double-blind, Three Arm, Parallel Group, Placebo-controlled, Randomized Study Designed to Evaluate the Efficacy, Safety and Tolerability of Dalfampridine.[NCT02271217]Phase 3377 participants (Actual)Interventional2014-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline on the Walking Impact Scale (Walk-12) at Week 12 (Key Secondary)

"The Walk-12 is a 12-question questionnaire that asks subjects to rate limitations of their mobility during the preceding two weeks on a 5-point scale (from 1= not at all to 5=extremely). For each visit, the Walk-12 score will be calculated by summing the 12 components and transforming into a scale with a range of 0 to 100. A higher score indicates a greater degree of limitation in walking. A negative change indicates an improvement in walking. 0 = no limitation in mobility to 100 extreme limitation in mobility.~Walk-12 Score = 100 * [(Mean of the 12 items) - 1]/(5-1)" (NCT02271217)
Timeframe: Baseline, week 12

Interventionunits on a scale (Mean)
Placebo45.40
Dalfampridine-ER 7.5 mg48.34
Dalfampridine-ER 10mg49.26

Proportion of Subjects Who Show at Least a 20% Improvement on the Two Minute Walk Test (2MinWT) at Week 12

"The 2MinWT measures the distance a subject can walk in 2 minutes. Participants showing at Least a 20% Improvement on the 2MinWT at 12-weeks are considered Responders." (NCT02271217)
Timeframe: Week 12

,,
Interventionparticipants (Number)
ResponderNon-ResponderMissing
Dalfampridine-ER 10mg23908
Dalfampridine-ER 7.5 mg17968
Placebo179712

Trials

1 trial available for 4-aminopyridine and Brain Ischemia

ArticleYear
A double-blind, randomized, controlled study of two dose strengths of dalfampridine extended release on walking deficits in ischemic stroke.
    Restorative neurology and neuroscience, 2020, Volume: 38, Issue:4

    Topics: 4-Aminopyridine; Adult; Brain Ischemia; Delayed-Action Preparations; Double-Blind Method; Humans; Is

2020

Other Studies

4 other studies available for 4-aminopyridine and Brain Ischemia

ArticleYear
Presynaptic K+ channel modulation is a crucial ionic basis of neuronal damage induced by ischemia in rat hippocampal CA1 pyramidal neurons.
    Zoological science, 2003, Volume: 20, Issue:1

    Topics: 4-Aminopyridine; Animals; Brain Ischemia; Excitatory Postsynaptic Potentials; Hippocampus; Potassium

2003
Zinc inhibits glutamate release via activation of pre-synaptic K channels and reduces ischaemic damage in rat hippocampus.
    Journal of neurochemistry, 2004, Volume: 90, Issue:5

    Topics: 4-Aminopyridine; Animals; Animals, Newborn; Brain Ischemia; Chelating Agents; Chlorocebus aethiops;

2004
K(ATP) channel blockers selectively interact with A(1)-adenosine receptor mediated modulation of acetylcholine release in the rat hippocampus.
    Brain research, 2001, Jan-19, Volume: 889, Issue:1-2

    Topics: 4-Aminopyridine; Acetylcholine; Adenosine; Animals; ATP-Binding Cassette Transporters; Binding, Comp

2001
K+ efflux pathways and neurotransmitter release associated to hippocampal ischemia: effects of glucose and of K+ channel blockers.
    Brain research, 1991, Jan-18, Volume: 539, Issue:1

    Topics: 4-Aminopyridine; Animals; Apamin; Aspartic Acid; Barium; Barium Compounds; Brain Ischemia; Calcium C

1991